Core Viewpoint - The A-share market is experiencing significant differentiation, with growth sectors facing both long-term opportunities from industrial upgrades and short-term impacts from macroeconomic fluctuations [1][2] Group 1: Fund Launch and Management - Morgan Huixi Growth Mixed Securities Investment Fund will officially launch on November 17, featuring a new floating management fee model aimed at enhancing investor experience by linking fees directly to fund performance [1] - The fund will be managed by experienced fund manager Li Dehui, who holds a PhD in Biomedical Engineering from Shanghai Jiao Tong University and has 13 years of securities research experience along with nearly 9 years in fund management [1] - Since Li Dehui took over the Morgan Technology Frontier Mixed Securities Investment Fund A-class shares in November 2016, the total return has exceeded 230% as of November 6, 2025, with a one-year return of over 50% [1] Group 2: Research and Market Outlook - Morgan Asset Management has a strong global research platform and deep local investment research capabilities, having been active in the mainland China market for 21 years, with an average of over 12 years of experience among its domestic active equity research team [2] - Looking ahead to the fourth quarter, factors such as expectations of Federal Reserve interest rate cuts, continued domestic liquidity, supportive policies, and resilient macroeconomic conditions are expected to benefit the overall A-share market [2] - The ongoing economic transformation in China has shown initial success, with investments in technology and domestic consumption expected to stabilize and drive future economic growth [2]

Core Insights - A total of 19 public funds have launched their initial fundraising on August 4, including three products from the second batch of new floating-rate funds: E Fund Value Return Mixed, China Europe Core Select Mixed, and Jianxin Medical Innovation Stock [1] Fund Details - China Europe Core Select Mixed is set to end its fundraising on August 15, E Fund Value Return Mixed on August 20, and Jianxin Medical Innovation Stock on August 22 [1] - Jianxin Medical Innovation has a fundraising cap of 3 billion yuan [1] Fund Management - E Fund Value Return is managed by Tang Bolun, Jianxin Medical Innovation by Ma Muqing, and China Europe Core Select by Zhang Cong and Song Ting [1] Fund Approval and Themes - The second batch of new floating-rate funds was approved on July 24, covering various industry themes such as pharmaceuticals, manufacturing, and high-end equipment, along with initiator funds [1] - Among the new products, there are 2 stock-type funds and 10 equity-mixed funds, including: Invesco Great Wall High-end Equipment Stock, Jianxin Medical Innovation Stock, Bank of China Quality Emerging Mixed, Ping An Research-Driven Mixed, Southern Ruijing Mixed, Oriental Red Medical Innovation Mixed, E Fund Value Return Mixed, Huatai-PB Manufacturing Theme Mixed, Guotai Quality Core Mixed, China Europe Core Select Mixed, and Morgan Huikai Growth Mixed [1]